BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

...to Quinn, Silence and the rest of the siRNA field pivoted from lipid nanoparticles to GalNAc-based...
...Silence “The GalNAcs also had challenges at first around dosing. But with more and more GalNAc...
...comfortable with the modality,” said Quinn. This time around, the partners will focus on the GalNAc...
BioCentury | Mar 4, 2020
Product Development

Biopharma broadens fight vs. COVID-19 as Alnylam, Takeda unveil new programs

...profits and losses associated with the program. While Alnylam’s programs typically target the liver via GalNAC...
BioCentury | Dec 17, 2019
Clinical News

Alnylam’s lumasiran is latest RNAi therapeutic to hit pivotal study goal

...to say how Alnylam expects to price the therapy, which targets glycolate oxidase using Alnylam’s GalNAc-conjugate...
BioCentury | Nov 22, 2019
Company News

Alnylam outlines ambitions, pipeline progress at R&D day

...with at least eight approved drugs and 10 late-stage clinical candidates by 2025, with safer GalNAc...
...on Friday, Alnylam reported safety data showing that neither of two candidates using its ESC+ GalNAc...
BioCentury | Jun 25, 2019
Preclinical News

Alnylam preclinical data latest sign companies still plugging away at oral oligos

...clinical results. In a presentation announced Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) showed that combining its GalNAc...
...oral formulation were similar to that induced by same GalNAc RNAi delivered subcutaneously. Versions of GalNAc...
BioCentury | May 3, 2019
Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

...Biosciences The first major breakthrough in cell type-specific delivery came with conjugation of oligos to GalNAc...
BioCentury | Mar 28, 2019
Translation in Brief

Tuning metabolism in liver organoids

...therapy Phase I/II for HBV, with Vir Biotechnology Inc. Both ALN-AAT02 and VIR-2218 use a GalNAc-conjugated...
BioCentury | Jan 31, 2019
Emerging Company Profile

Apic: Dual-gene therapies

...company has ALN-AAT02, a version of ALN-AAT that uses Alnylam's enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate...
BioCentury | Dec 14, 2018
Financial News

Janssen veterans raise $13M for Centyrin platform

...that are not really accessible for targeted siRNA delivery," O'Neil said. She pointed to the GalNAc...
BioCentury | Dec 11, 2018
Financial News

Janssen veterans raise $13M for Centyrin platform

...that are not really accessible for targeted siRNA delivery," O'Neil said. She pointed to the GalNAc...
Items per page:
1 - 10 of 109